Clinical Trials Logo

Clinical Trial Summary

This study aims to screen and validate multi-scale bio-markers for early diagnosis and medication monitoring for early schizophrenia, including the genetic, neurobiochemistry, neuroimaging and eletrophysiological measures. Based on the validated bio-markers, the present study further tries to build several prediction models for early differential diagnosis of schizophrenia from healthy controls and other mental diseases (such as the major depression and anxiety disorders), biological sub-typing and diagnosis of the schizophrenia sub-types, and early prediction of the medication effects.


Clinical Trial Description

Schizophrenia is one of the most important diseases that threaten the health of Chinese people. In view of the current lack of objective biological markers in the diagnosis and treatment of schizophrenia, as well as the lack of effective early diagnosis methods and curative effect prediction methods, the investigators carried out joint research by integrating research teams from molecular genetics, neurobiochemistry, psychiatry, medical imaging, information science and other fields. The overall objective of the project is to establish a bio-marker system for individualized diagnosis and treatment of early schizophrenia. Specific research contents include: screening and verifying multidimensional objective biological markers such as genetics, neurobiochemistry, neuroimaging, electrophysiology, which is related to early diagnosis and efficacy prediction of schizophrenia through big data analysis of healthy controls and patients with first episode schizophrenia, depression and anxiety disorder. Pattern recognition method is used to build the individualized early diagnosis model, biological sub-type clustering model, biological sub-type individualized diagnosis model and early curative effect prediction model of schizophrenia. Based on the individualized diagnosis and treatment prediction model of schizophrenia, the individualized diagnosis and treatment toolkit was developed, and the individualized diagnosis and treatment prediction cloud platform was established to provide assist for clinicians. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03790085
Study type Interventional
Source Tianjin Medical University General Hospital
Contact Chunshui Yu, MD
Phone 862260363760
Email chunshuiyu@vip.163.com
Status Recruiting
Phase Early Phase 1
Start date September 1, 2018
Completion date December 31, 2020

See also
  Status Clinical Trial Phase
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Recruiting NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Recruiting NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A
Completed NCT02304432 - Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine Early Phase 1
Completed NCT01412060 - A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia Phase 3
Completed NCT01222793 - Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia N/A
Enrolling by invitation NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Recruiting NCT02868879 - Anatomical and Structural Connectivity in Two Psychotic Phenotypes : Periodic Catatonia and Cataphasia
Completed NCT02212041 - Electronic Cigarettes in Smokers With Mental Illness N/A
Completed NCT01878513 - Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis N/A
Recruiting NCT03163706 - Evaluation of Stroop Effect in Patients With Schizophrenia N/A
Completed NCT00001921 - Electrophysiology and Blood Flow in Patients With Schizophrenia and Their Siblings
Not yet recruiting NCT03807388 - ReMindCare App for Patients From First Episode of Psychosis Unit. N/A
Recruiting NCT02796144 - MEtformin and Lorcaserin for WeighT Loss in Schizophrenia Phase 4
Recruiting NCT02864576 - Cognitive Remediation Plus Aerobic Exercise in Schizophrenia Treatment N/A
Recruiting NCT02906553 - The Role of Nitric Oxide in Cognition in Schizophrenia N/A
Recruiting NCT02823041 - Enhancing Cognitive Training Through Exercise Following a First Schizophrenia Episode N/A